What’s the news?

The ninth edition of the Global Health Exhibition is scheduled to take place at the Riyadh Exhibition and Convention Center, known as Malham, from 26 to 29 October 2026. Organized under the patronage of the Ministry of Health, the event carries the theme “Invest in Health” and is expected to bring together investors, researchers, policymakers, and health sector leaders from across the world.

The announcement follows a strong showing at the eighth edition, where signed agreements exceeded SAR 133 billion. The event hosted 2,200 brands, featured 600 global health leaders as speakers, and welcomed more than 130,000 visitors. International attendance rose by 54% compared to prior editions, a sign that global interest in Saudi Arabia’s health sector is not simply diplomatic rhetoric but is translating into real commercial engagement.

Why does it matter?

The numbers from last year’s edition are hard to ignore. A sixfold increase in private-sector deals is not incremental progress. It reflects a shift in how international investors and health companies are positioning themselves relative to the Kingdom’s market. Saudi Arabia has moved from being a buyer of health services to becoming a destination for health investment, research partnerships, and technology deployment.

The 2026 edition is expected to build on that momentum. Organizers describe the event as a platform designed to attract high-potential investments, support strategic partnerships, and showcase technologies shaping the future of healthcare delivery. The Ministry of Health is already inviting professionals and stakeholders to register their participation ahead of the event.

The context

The Global Health Exhibition sits firmly within the Health Sector Transformation Program, one of the core pillars of Saudi Vision 2030. The program’s goals are clear: reduce dependence on oil revenue by building a productive private health sector, improve the quality and accessibility of care for Saudi citizens, and position the Kingdom as a regional center for medical research and innovation.

Progress on those goals has been visible. Private health insurance penetration is rising. Hospital privatization has accelerated. And international health companies, from diagnostics firms to digital health platforms, are establishing a local presence in Riyadh and Jeddah at a pace that would have been unusual five years ago.

The GCC context matters here too. The UAE has its own health investment ambitions, and Qatar continues to develop its national health strategy. But Saudi Arabia’s scale, its young population, and the sheer volume of capital flowing through Vision 2030 give Riyadh a structural advantage in attracting the kind of long-term health investment that drives system-wide change. The Global Health Exhibition has become one of the clearest annual indicators of how that advantage is being used.

Professionals and organizations interested in participating in the ninth edition can register directly through the official Global Health Exhibition website.

The post Saudi Arabia’s Global Health Exhibition returns in 2026 with record ambitions appeared first on DH Arab.

Right now, that information sits across multiple systems. Clinicians often cannot access the full picture at the point of care, and researchers face delays in translating data into discovery. This collaboration, if formalised, would use Oracle’s cloud infrastructure, connected data platform, and AI capabilities to close that gap. The initiative also directly supports the healthcare transformation targets set out under Saudi Vision 2030, which has made the Kingdom’s position as a global health innovation hub a stated national priority.

How will it work?

The two organisations are exploring four areas of collaboration:

• Connecting data across the healthcare ecosystem to strengthen care coordination
• Advancing personalised medicine by drawing on clinical, genomic, and research insights to tailor prevention, diagnosis, and treatment
• Applying responsible AI to give clinicians relevant, timely information at the point of care
• Accelerating biomedical discovery to bring new research findings into patient care faster

Oracle’s secure cloud infrastructure would sit at the centre of this effort, providing the architecture needed to bring previously siloed information together. The intended result is a system where care teams receive the right insights at the right moment, and researchers can move from raw data to actionable findings more quickly.

Why does it matter?

KFSH is ranked first in the Middle East and Africa and 12th globally among the world’s top 250 academic medical centres for 2026. It also holds the title of most valuable healthcare brand in Saudi Arabia and the Middle East, according to Brand Finance, and appears on Newsweek’s lists of the World’s Best Hospitals, World’s Best Smart Hospitals, and World’s Best Specialized Hospitals for 2026. So when KFSH signals a strategic direction, the regional health sector tends to follow.

The broader significance here is the combination of genomic data and clinical records within a single AI-enabled platform. Personalised medicine has long been discussed in the GCC as a future aspiration. A working model at this scale, anchored by one of the region’s most credible institutions, would move that conversation considerably further forward.

The context

Saudi Arabia has invested heavily in digital health infrastructure over the past several years, and Vision 2030’s Health Sector Transformation Program has set targets around preventive care, hospital efficiency, and research capacity. But the challenge across the region, and indeed globally, has always been integration. Data exists. The problem is that it rarely talks to itself.

This is also part of a wider pattern of Gulf health institutions forming technology partnerships with major US cloud and AI companies. The KFSH-Oracle announcement reflects a maturing approach, one that moves beyond electronic records and toward genuinely intelligent, data-connected care. Whether the collaboration produces results at the scale it promises will depend on execution. But the direction is clear, and the institutional weight behind it is real.

The post KFSH and Oracle Health to build a unified clinical and genomic data ecosystem in Saudi Arabia appeared first on DH Arab.

What’s the news?

KPMG selected SDM from a field of ten finalists at the Saudi edition of its annual competition, which was held for the sixth time this year. The judging panel assessed companies across several criteria:

• Strength and originality of the technology
• Market potential and customer traction
• Long-term growth potential
• Quality of the pitch

SDM develops AI-driven diagnostic tools, with a particular focus on retinal imaging technology designed to support early detection of chronic and systemic diseases. The other finalists included Authena, Carevision, Eyego, LinusBio, Nommas, Plantafarm, Terraxy, Think AI, and WhiteHelmet, spanning sectors from agriculture and food supply chains to construction and space technology.

Why does it matter?

SDM’s win is more than a competition result. It points to something broader happening in Saudi Arabia’s technology sector. Naif AlObaidallah, CEO of SDM, was direct about the significance: “What we have built was born in Saudi Arabia, developed by Saudi talent, and designed for the healthcare needs of our people.” That framing matters. Saudi Arabia has spent years positioning itself as a consumer and importer of global technology. The push now, embedded in Vision 2030, is to become a producer and exporter of it.

Samer Abdallah, Partner and Board Member at KPMG in the Middle East and chair of the judging panel, said SDM stood out for combining a credible technology proposition with clear real-world application and the ability to scale. In health-tech, that combination is harder to achieve than it sounds. Many AI diagnostic tools struggle to move from pilot to clinical adoption. SDM’s traction with customers was clearly part of what convinced the panel.

The context

The KPMG Global Tech Innovator competition runs across more than 20 countries, with national winners competing at a single global final. It gives early and growth-stage technology companies exposure to KPMG’s advisory networks, access to investors, and a platform that most startups would otherwise take years to reach.

For the Gulf health-tech sector, moments like this carry real weight. The UAE has its own aggressive digital health agenda, and Saudi Arabia’s Vision 2030 has made health system modernisation a stated national priority. AI-assisted diagnostics, particularly tools that can support detection of conditions like diabetes and cardiovascular disease, which carry a significant disease burden across the GCC, are exactly the kind of home-grown solutions policymakers have been calling for.

So when SDM takes the stage in Lisbon in November, it will carry more than a competition title. It will carry a case study in what Saudi deep tech can look like when the conditions are right.

The post Saudi health-tech firm SDM wins KPMG’s 2026 Global Tech Innovator competition appeared first on DH Arab.

What’s the news?

GHE has confirmed its speaker lineup for the 2026 edition, taking place from October 26 to 29 at Riyadh Exhibition and Convention Center in Malham. More than 500 global speakers will appear across four dedicated conference stages, covering healthcare leadership, clinical innovation, digital health, and investment.

The Leaders’ Summit will bring together senior executives and policymakers to discuss how health systems can drive economic growth, integrate AI, and shift from reactive treatment toward prevention and long-term wellbeing. Speakers include GE HealthCare Chief Commercial and Growth Officer Catherine Estrampes and GSK Chair Jonathan Symonds.

The MEDX Forum will focus on translating clinical research into patient care, from advanced therapies to predictive diagnostics. Professor Declan O’Regan, who holds the British Heart Foundation Chair of Cardiovascular AI at Imperial College London, will appear alongside Dr. Samuel Sia from Columbia University. The Digital Health Forum features Professor Shafi Ahmed of Barts Health NHS Trust and Dr. Tamara Sunbul, Group CIO at Fakeeh Care Group and Co-Chair of the Global Digital Health Partnership’s Evidence and Evaluation Workstream. The Capital Xchange Forum addresses investment strategy, with speakers from SoftBank Vision Fund, Blackstone, and Mayo Clinic’s corporate development team.

New additions for 2026 include:

• Leaders’ Club, an exclusive network for senior healthcare decision-makers
• Pulse Studio, a live podcast recording space
• HealthTech Live, for live technology demonstrations
• Power Breakfast Series, focused sessions on capital, policy, and priorities
• Reverse Pitching, where corporations present strategic needs directly to startups
• Unplugged Lounge, informal networking space outside the main program

Why does it matter?

The speaker list alone tells you something. When SoftBank, Blackstone, and Mayo Clinic send senior figures to a healthcare conference in Riyadh, it reflects a genuine commercial interest, not just diplomatic goodwill. Saudi Arabia is moving capital into healthcare at scale, and international investors are paying attention.

Rachel Sturgess, Executive Vice President at Tahaluf, put it plainly: “The caliber of leaders coming to Riyadh to be part of that conversation reflects the scale of the opportunity here.” That’s a fair read. GHE is not just a venue for ideas. It’s a place where deals get framed, partnerships get started, and market entry strategies get tested against real decision-makers.

The context

Saudi Arabia’s Vision 2030 has set an explicit goal of reducing the country’s dependence on oil revenue, and healthcare is one of the sectors carrying real weight in that strategy. The Kingdom is investing heavily in hospital infrastructure, digital health systems, and biomedical research capacity. The government wants to attract foreign direct investment, build local clinical expertise, and shift public health outcomes from treatment to prevention.

GHE sits directly inside that agenda. It is organized by Tahaluf, a joint venture between Informa Markets and the Saudi Federation for Cybersecurity, Programming and Drones, which gives it both commercial credibility and institutional backing. Foundation Partners Dallah Health and Hayat National Hospital reflect the domestic health sector’s engagement, while international partners including Novartis, Stryker, Johnson and Johnson, and Canon Medical Systems signal that global industry sees Saudi Arabia as a priority market, not an afterthought.

So the question for healthcare professionals and business leaders attending is not whether Saudi Arabia is a serious player in the regional health economy. It clearly is. The more interesting question is how quickly the country can translate this level of international engagement into measurable improvements in patient outcomes, and GHE 2026 is where some of those answers will start to take shape.

The post Global Health Exhibition 2026 brings 500 speakers to Riyadh for its biggest edition yet appeared first on DH Arab.

The Saudi Food and Drug Authority (SFDA) has granted marketing authorization to two AI-enabled medical software products: “Dental IQ,” designed to support dental diagnosis, and “SAARIA,” built for retinal screening in diabetic patients. Both were developed by Saudi startups and both went through the SFDA’s Innovative Medical Devices Pathway, which offers early regulatory guidance to companies bringing novel technologies to market. Local clinical studies were conducted in the Kingdom to validate performance under real-world conditions, and both companies have committed to post-marketing follow-up to monitor how the tools perform in practice.

How does it work?

Dental IQ uses deep learning algorithms to analyze dental X-ray images. It flags potential findings such as dental caries, periodontal disease, and structural changes in teeth and surrounding tissues. The aim is to give practitioners a more consistent second read, supporting diagnostic accuracy and treatment planning.

SAARIA analyzes retinal fundus images using AI to screen diabetic patients for signs of diabetic retinopathy. Early detection is the core objective. The software is designed to identify patients who may need specialist evaluation, helping to speed up referral before the condition progresses. Diabetic retinopathy remains one of the leading causes of preventable blindness globally, and in the GCC, where diabetes prevalence is among the highest in the world, the clinical need is acute.

Both products are positioned as clinical support tools, not autonomous decision-makers. The SFDA has been clear on this point: AI outputs are intended to inform clinical judgment, not replace it. Healthcare professionals retain full responsibility for reviewing findings and making decisions based on each patient’s condition.

Why does it matter?

The GCC has no shortage of imported health technology. What it has historically lacked is domestically built, domestically validated medical software. These two approvals change that, at least in part. They show that local companies can produce AI tools that meet regulatory standards, conduct rigorous clinical studies, and bring a product to market through formal channels.

There are also practical benefits specific to the region. AI models trained and validated on local patient populations, with the demographic and epidemiological characteristics of Saudi Arabia, are more likely to perform reliably in Saudi clinical settings than tools developed elsewhere. That matters especially for diabetic retinopathy screening, where early, accurate detection can prevent blindness in a high-risk population.

The context

These approvals sit within a broader policy push. Saudi Arabia’s Health Sector Transformation Program, one of the pillars of Vision 2030, has set explicit targets around digital health adoption, local industry development, and improved patient outcomes. Regulatory bodies like the SFDA have a direct role in that agenda, and the Innovative Medical Devices Pathway was built precisely to support companies that might otherwise struggle with the time and complexity of standard regulatory processes.

Across the GCC, regulators are working to build frameworks that can keep pace with AI in healthcare without sacrificing safety. The UAE has its own digital health strategy and the Dubai Health Authority has been active in piloting AI clinical tools. But approvals of locally developed AI medical software, validated through domestic clinical studies, are still relatively rare in the region. Saudi Arabia has now set a reference point. Other GCC markets will be watching.

The post Saudi Arabia clears its first homegrown AI diagnostic tools for dentistry and eye disease appeared first on DH Arab.

King’s Jeddah opened in 2025 as an extension of King’s College Hospital London, a teaching institution founded in 1840. It operates under the same UK clinical protocols as its London counterpart and has over 130 specialist consultants across 35 clinical specialties and 10 centres of excellence. That’s a significant clinical footprint, and it demands a digital infrastructure to match.

The hospital has been running InterSystems TrakCare as its core EHR since opening. The move to IntelliCare is not a switch from a failing system. It’s a progression from one that worked. That distinction matters. The clinical and operational teams already understand the InterSystems environment, which means the transition carries less disruption risk and more institutional confidence behind it.

Dr. Ibrahim Alharfi, Chief Executive Officer of King’s College Hospital London – Jeddah, put it plainly: “Technology is not the destination; better patient outcomes are. Adopting InterSystems IntelliCare enables our teams to work with greater intelligence, reduce avoidable delays, and keep the clinician’s attention where it belongs: on the patient in front of them.”

How will it work?

IntelliCare is built on the TrakCare foundation but designed to embed AI directly into clinical workflows rather than sitting alongside them. For King’s Jeddah, the platform will introduce several key capabilities:

• Ambient clinical documentation: AI listens to clinical conversations and converts them into structured records automatically, cutting the time clinicians spend typing.
• Built-in AI workflow intelligence: Intelligence is present at every step, from ordering and prescribing to reviewing results, without requiring separate integrations.
• Clinician-centred design: The system is built to minimise the friction technology creates during patient encounters.
• Enhanced interoperability: Full support for HL7 FHIR and SMART on FHIR standards, connecting the hospital within Saudi Arabia’s broader health data ecosystem.

Diaa Kamal, Chief Information Officer at King’s Jeddah, described the platform as one where “AI surfaces the right information at the right moment, documentation happens naturally, and workflows adapt to the clinician rather than the other way around.”

Why does it matter?

The EMEA-first status is notable, but the more significant point is what this reflects about Saudi Arabia’s trajectory in healthcare technology. The Kingdom’s Vision 2030 health agenda has consistently pushed institutions to raise care quality while reducing inefficiencies. AI-embedded clinical systems are a direct answer to both goals.

Ambient documentation alone addresses one of the most persistent complaints from clinicians globally: that they spend more time with screens than with patients. If IntelliCare delivers on that promise at King’s Jeddah, it will carry weight far beyond one hospital’s deployment.

Ali Abi Raad, Managing Director of InterSystems Middle East, India and South Africa, said King’s Jeddah is “perfectly positioned to realise the full potential of IntelliCare,” pointing to the hospital’s existing foundation on TrakCare as the basis for that confidence.

The context

Saudi Arabia has invested heavily in health digitisation over the past several years, with the Ministry of Health pushing EHR adoption across public and private sectors alike. But the conversation is shifting. Basic digitisation is largely done. The question now is what healthcare institutions do with the data they are collecting and how intelligently their systems can act on it.

King’s Jeddah’s decision to adopt an AI-native EHR places it at the front of that conversation in the region. And because it sits within a globally recognised clinical brand, with strong academic oversight and measurable outcome standards, what happens there will be watched closely by peers across the GCC. This is the kind of deployment that tends to set direction for others.

The post King’s College Hospital Jeddah to become first hospital in EMEA to run InterSystems IntelliCare appeared first on DH Arab.

The centerpiece of the trip was a bilateral meeting with Portuguese Health Minister Ana Paula Martins, during which both sides agreed to formalise their cooperation through a new MoU. The agreement sets out a framework for joint work across healthcare delivery, innovation, and digital health, with a focus on areas that both countries have identified as priorities. The stated goals include improving the efficiency and sustainability of health services in both countries.

Al-Jalajel also met with Adalberto Campos Fernandes, an adviser to the Portuguese President currently overseeing the preparation of Portugal’s Strategic Health Pact and a former health minister in his own right. That conversation focused on health system strategy, population health, and disease prevention. And in a separate meeting, Minister for State Reform Gonçalo Matias discussed institutional transformation, performance efficiency, and the role of AI and digital tools in reshaping public health systems. Saudi Ambassador to Portugal Ali bin Abdulrahman Al-Yousef attended both of those sessions.

How will it work?

The MoU establishes a structured basis for cooperation rather than a single project. In practice, that means the two ministries are committing to:

• Exchange of expertise and leading practices across healthcare delivery
• Joint work on digital health and health innovation
• Cooperation on institutional reform and system performance
• Knowledge sharing on priority health issues of mutual interest
• Support for health research and scientific collaboration

Al-Jalajel also visited Santa Maria University Hospital and the Gulbenkian Institute for Molecular Medicine, two institutions with strong reputations in clinical practice and biomedical research. Both visits included discussions on potential areas for future collaboration, including health research and the use of innovative technologies in care delivery.

Why does it matter?

Saudi Arabia’s Vision 2030 health agenda is well known domestically. What is becoming clearer is how actively the Kingdom is exporting that agenda internationally, using bilateral partnerships to benchmark its reforms, attract expertise, and position itself as a credible voice in global health governance. Portugal, with a public health system that has undergone significant structural change over the past decade, is a useful reference point. The inclusion of AI and digital transformation in the ministerial discussions also reflects where Saudi health policy is headed. The Kingdom has made significant investments in health data infrastructure and digital services, and agreements like this one help build the international networks needed to advance that work.

The context

This visit is part of a broader pattern. Saudi Arabia has been steadily expanding its international health partnerships over the past several years, engaging with European governments, multilateral health bodies, and academic institutions. The framing of each engagement, including this one, consistently references the Kingdom’s own reform experience as something worth sharing, not just learning from. That shift in posture matters. It reflects a country that sees itself as a contributor to global health thinking, not just a recipient of it. For GCC health professionals and policymakers watching from across the region, the Saudi approach offers a potential model for how national reform agendas can be amplified through strategic international engagement.

The post Saudi health minister signs MoU with Portugal in push to build global health partnerships appeared first on DH Arab.

Health diplomacy is increasingly central to how Gulf states project soft power and build long-term national capability. Saudi Arabia has been particularly active in this space, using bilateral agreements to accelerate progress across its healthcare sector as part of Vision 2030’s ambitious targets, which include reducing the Kingdom’s dependence on expatriate medical labor, expanding local pharmaceutical manufacturing, and improving health outcomes for a rapidly growing and aging population.

France, for its part, is one of Europe’s most respected healthcare systems. It has deep experience in hospital management, medical education, and pharmaceutical research. So this is not a partnership built on prestige alone. There is real substance to draw from on the French side.

How will it work?

The specific terms of the MoU have not been disclosed. But based on the structure of similar agreements Saudi Arabia has signed in recent years, these frameworks typically cover a range of cooperation areas, including:

• Exchange of medical expertise and training programs
• Joint research and clinical collaboration
• Knowledge transfer in hospital administration and health system management
• Potential pharmaceutical and medical technology partnerships

MoUs of this kind are not binding contracts. They are frameworks that signal political intent and open formal channels for negotiation. The real outcomes depend on what gets built on top of them.

Why does it matter?

Saudi Arabia is spending heavily on healthcare. The sector is one of the core pillars of Vision 2030, with billions earmarked for new hospitals, digital health infrastructure, and medical city development. But capital alone does not build a world-class health system. You need clinical expertise, institutional knowledge, and trained professionals. That’s where international partnerships come in.

A formal agreement with France also fits into a broader Gulf pattern. The UAE has signed health cooperation agreements with dozens of countries. Qatar used the World Cup to accelerate health infrastructure deals. Saudi Arabia is now moving with similar intent, using high-profile diplomatic moments to lock in long-term relationships.

The context

Crown Prince Mohammed bin Salman’s visit to France was one of the most significant Saudi diplomatic engagements of the year, covering defense, trade, and cultural ties. The health MoU was one of several agreements signed during the visit. It may not have been the headline, but for those watching Saudi Arabia’s healthcare transformation closely, it is worth tracking. Agreements like this one tend to quietly shape the sector for years to come.

The post Saudi Arabia and France sign health MoU during Crown Prince’s Paris visit appeared first on DH Arab.

The platform launched publicly in August after operating quietly across Saudi Arabia and Qatar since earlier in the summer, where it has already been used by thousands of people researching aesthetic and plastic surgery procedures. It answers questions in Arabic, accounts for dialect differences across the Gulf, and does not push users toward any particular provider or outcome. The decision stays with the patient. Zaina just makes sure they arrive at it better prepared.

“A purchase ends at the counter. This one stays with you,” said Eng. Fernando Rojas, Head of Health Ventures and Managing Partner GCC at The Agile Monkeys. “The smartest thing anyone can do is walk into that consultation already understanding what they are asking about. Explaining something this complex, in Arabic, at whatever hour someone is thinking about it, was not possible until very recently. It is now.”

How does it work?

Zaina operates as a conversational assistant, meaning users interact with it the way they would a knowledgeable contact rather than a search engine. It is built to explain:

• How different procedural approaches compare across providers
• What recovery genuinely involves, not the sanitised version
• Which questions are worth raising in a clinical consultation
• The range of outcomes associated with specific procedures

The platform handles Arabic-language input and is built to recognise dialectal variation across the GCC, which matters in a region where a formal Modern Standard Arabic interface can feel cold or inaccessible to everyday users. Rojas was direct about where the real difficulty lies: “The model is the easy part. Making it work inside a regulated field, safely, every day, is the serious part.”

Why does it matter?

Better-informed patients are not just good for patients. Clinics that compete on clinical quality rather than marketing budgets benefit when someone arrives at a consultation already understanding the procedure, the alternatives, and the realistic outcomes. That shifts the conversation from persuasion to evaluation, which is where it should start.

So there is a commercial logic here alongside the patient safety argument. Providers who rely on substance over advertising spend are naturally advantaged when the person across the desk already knows what questions to ask. Zaina does not refer patients to clinics, which keeps its position neutral and its advice credible.

The context

The Agile Monkeys is a Spanish AI engineering firm that builds products for regulated industries, including health, retail, and financial services, across Europe, the United States, and the Gulf. Its expansion into aesthetic medicine reflects a broader pattern across the GCC, where Vision 2030 in Saudi Arabia and parallel digital health strategies in the UAE are creating real appetite for AI-backed patient engagement tools.

Aesthetic medicine is a sector that has largely been left out of that conversation, treated as adjacent to healthcare rather than part of it. But the procedures involved carry genuine clinical risk and the decisions are permanent. Closing the information gap in Arabic, in a region where the market for aesthetic procedures is growing fast, addresses something that has been overlooked for a long time.

The company has confirmed plans to expand into Dubai in the fourth quarter of 2026.

The post Zaina brings Arabic-language AI to aesthetic medicine in Saudi Arabia and Qatar appeared first on DH Arab.

The agreement does not commit either party to specific projects immediately. Instead, it creates a structured platform through which the two organisations can identify where their respective strengths align and where joint activity makes sense. SNIH brings a national mandate for health research; Sanofi brings decades of clinical development experience across global markets. The question the MoU asks is: what can those two things produce together inside Saudi Arabia?

Areas of potential cooperation include research into diseases with a high burden in the Saudi population, genomics and precision medicine tailored to local genetic profiles, and the application of artificial intelligence, digital biomarkers, and real-world evidence in health research. Any work involving national health or genomic data will require separate agreements and approval from the relevant Saudi authorities.

How will it work?

The framework organises potential cooperation around three broad areas:

• Research and innovation, including genomics, precision medicine, and AI-driven analytics relevant to Saudi disease priorities
• Capability development in research methodology, clinical trial conduct, regulatory science, bioethics, bioinformatics, and health data science
• Knowledge exchange, covering scientific methodologies, governance practices, and international standards to support Saudi research infrastructure

Prof. Fars Alanazi, Chief Executive Officer at SNIH, described the goal as building a national research ecosystem that is “globally connected and locally rooted.” Dr. Lama Saleh, Sanofi’s General Manager for General Medicines in Saudi Arabia and Gulf Countries, framed it similarly, saying the country is moving from participating in global health research to originating it. But she was clear that the shift requires more than funding. It requires talent, infrastructure, and an ecosystem capable of translating discovery into outcomes.

Why does it matter?

Clinical trials have historically been concentrated in Europe, North America, and parts of Asia. Gulf populations, with their distinct genetic profiles and disease patterns, are often underrepresented in the studies that generate the evidence base for global medicine. An agreement that builds local clinical trial readiness and invests in Saudi scientific talent addresses that gap directly.

There is also a practical economic argument. Research and development activity generates high-value jobs, attracts international scientific networks, and supports a pharmaceutical and biotech sector that Saudi Arabia is actively trying to grow. The National Biotechnology Strategy, referenced explicitly in the MoU, puts that ambition in policy terms.

The context

This agreement sits inside a much broader push across the GCC to shift health systems from reactive care to research-led, data-driven medicine. Saudi Vision 2030 and the Health Sector Transformation Program both identify research capacity as a national priority, not a peripheral one. The UAE has made similar moves, investing heavily in genomics through programs like the Emirates Genome Council. So the regional direction is consistent.

What makes the SNIH-Sanofi framework notable is its specificity around capability building. It is not simply a commercial partnership. It is, at least in stated intent, an attempt to ensure that the next generation of Saudi clinicians and scientists can lead research rather than just participate in it. Whether that intent translates into measurable outcomes will depend on the concrete projects that follow.

The post SNIH and Sanofi sign MoU to build Saudi Arabia’s health research capacity appeared first on DH Arab.